News
SCD, beta-thalassemia: CRISPR-based gene therapy `transformative’
- Author:
- Nancy A. Melville
Phase 3 results suggest potential for a “functional cure”; this treatment could become first-ever approved CRISPR gene-editing therapy.
News
PV: Novel rusfertide shows ‘impressive’ efficacy
- Author:
- Nancy A. Melville
The novel synthetic form of liver hormone hepcidin represents a “paradigm shift” in polycythemia vera treatment, allowing patients to avoid the...
News
Multiple sclerosis has a misdiagnosis problem
- Author:
- Nancy A. Melville
Experts warn that false-negative diagnoses cause treatment delays, while false-positive diagnoses run the risk for potential harm from needless...
News
‘Best’ for most APL patients: Chemo-free regimen
- Author:
- Nancy A. Melville
A chemo-free treatment regimen significantly improves survival over chemotherapy in patients with a rare, virulent leukemia, but those 50 and...
News
Antibiotic prophylaxis may lower SSIs in skin cancer surgery
- Author:
- Nancy A. Melville
There’s a lack of evidence from randomized clinical trials of the role of antibiotic prophylaxis in reducing SSI rates among patients undergoing...
News
‘Strikingly positive’ effect of novel MS agent
- Author:
- Nancy A. Melville
Frexalimab is a novel second-generation monoclonal antibody designed to block the costimulatory CD40/CD40L cellular pathway.
News
`Remarkable’: CAR T therapy for CLL/SLL
- Author:
- Nancy A. Melville
Primary analysis of the TRANSCEND CLL 004 trial showed that a single dose of CAR T therapy achieved durable responses in CLL and SLL, with a...
News
PMBCL: Postremission, patients may safely skip radiation
- Author:
- Nancy A. Melville
Among patients who had achieved complete remission of primary mediastinal B-cell lymphoma with chemotherapy, the largest study of its kind found...
News
Multiple changes in NMOSD treatment for nonmedical reasons tied to poorer outcomes
- Author:
- Nancy A. Melville
“Our data highlight that aspects outside of therapeutic efficacy may be remarkably meaningful in the effective suppression of disease advancement...
News
Long-term freedom from NMOSD relapse with satralizumab
- Author:
- Nancy A. Melville
At week 240 (4.6 years), 72% of satralizumab-treated patients were relapse-free, with 91% free from severe relapse.
News
Groundbreaking new regimen for advanced Hodgkin lymphoma
- Author:
- Nancy A. Melville
The immune checkpoint inhibitor nivolumab affords unprecedented improvement in “harmonizing” treatment for adult and pediatric Hodgkin lymphoma...
News
Endocrinology pay steadily climbs, gender gap closes
- Author:
- Nancy A. Melville
Endocrinologists’ earnings still place them in the lowest five specialties in terms of pay, above infectious diseases, family medicine, pediatrics...
News
'Paradigm shift’: Luspatercept for MDS
- Author:
- Nancy A. Melville
In a first head-to-head comparison study, luspatercept for MDS significantly outperformed epoetin alfa in reducing transfusion dependence.
News
Diabetes, cholesterol meds use drops after bariatric surgery
- Author:
- Nancy A. Melville
Undergoing bariatric surgery was associated with a substantial and long-lasting reduction in the use of lipid-lowering and antidiabetic...
News
Immunotherapy plus chemo improves quality of life in NSCLC
- Author:
- Nancy A. Melville
The delays reported in time to definitive clinically meaningful deterioration “are particularly pertinent, given the anticipated continued...